Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-206RY
- Development stage
- Phase 1
- Lead developer
- ViroMed
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VM-206RY is a therapeutic cancer vaccine developed as a heterologous prime-boost vaccination regimen targeting HER2-expressing tumors. The vaccine consists of two components—a plasmid DNA (pHM-GM-CSF) and an adenoviral vector (Ad-HM)—administered sequentially to stimulate both cellular and humoral immune responses against the HER2 antigen. It has been investigated primarily in patients with HER2-positive breast cancer but is also intended for other solid tumors expressing HER2/neu. The primary mechanism involves modulation of the receptor protein-tyrosine kinase erbB-2 (HER2), aiming to induce anti-tumor immunity. Clinical studies have focused on safety, tolerability, immunogenicity, and preliminary efficacy in solid tumors[1][2][3].
- Other names
- VM 206VM206VM-206
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on VM-206RY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-206RY.